Pharmacotherapy Original research| Volume 34, ISSUE 8, P1720-1734.e3, August 2012

I-ADD Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled With Irbesartan 150 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded–End Point Evaluation Study

  • Guillaume Bobrie
    Address correspondence to: Guillaume Bobrie, MD, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
    Department of Hypertension Hôpital Européen Georges Pompidou, Paris, France
    Search for articles by this author
  • I-ADD Study Investigators
    Author Footnotes
    ⁎ Members of the I-ADD Study Investigators are listed in the Acknowledgments.
  • Author Footnotes
    ⁎ Members of the I-ADD Study Investigators are listed in the Acknowledgments.



      Hypertension guidelines recommend the use of 2 agents with synergistic action when >1 agent is needed to achieve blood pressure goals. Newer antihypertensive treatment combinations include fixed-dose combinations of an angiotensin receptor blocker and a calcium channel blocker.


      The I-ADD study aimed to demonstrate whether the antihypertensive efficacy of fixed-dose combination irbesartan 300 mg/amlodipine 5 mg (I300/A5) was superior to that of irbesartan (I300) monotherapy in lowering home systolic blood pressure after 10 weeks' treatment.


      The I-ADD study was a 10-week, multicenter, Phase III, prospective, randomized, parallel-group, open-label with blinded–end point study. The main inclusion criterion was essential uncontrolled hypertension (systolic blood pressure ≥145 mm Hg at office after at least 4 weeks of irbesartan 150 mg [I150] monotherapy administered once daily). Patients continued to receive I150 for 7 to 10 days and were randomized to either monotherapy with I150 for 5 weeks then I300 for the next 5 weeks, or to a fixed-dose combination therapy (I150/A5, then I300/A5). Safety profile was assessed by recording adverse events reported by patients or observed by the investigator.


      Following enrollment, 325 patients were randomized to treatment, and 320 (mean [SD] age, 56.7 [11.4] years; 41% male) were included in the intention-to-treat analysis: 155 patients treated with I150/A5 then I300/A5, and 165 patients treated with I150 then I300. At randomization, mean home systolic blood pressure was similar in both groups: 152.7 (11.8) mm Hg in the I150/A5 group and 150.4 (10.1) mm Hg in the I150 group. At week 10, the adjusted mean difference in home systolic blood pressure between groups was –8.8 (1.1) mm Hg (P < 0.001). The percentage of controlled patients (mean home blood pressure <135 and 85 mm Hg) was nearly 2-fold higher in the I300/A5 group versus the I300 group (P < 0.001). Treatment-emergent adverse events were experienced by 10.5% of I300/A5-treated patients and 6.6% of I300-treated patients during the second 5-week period. Three serious adverse events were reported; 2 with monotherapy (1 with I150 and 1 with I300) and 1 with fixed-dose combination I300/A5. All patients affected by serious adverse events made a full recovery.


      These 10-week data from this patient population suggest a greater antihypertensive efficacy of the fixed-dose combination I300/A5 over I300 alone in lowering systolic blood pressure. Both treatments were well tolerated throughout the study. identifier: NCT00957554.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mancia G.
        • De Backer G.
        • Dominiczak A.
        • et al.
        2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
        J Hypertens. 2007; 25: 1105-1187
        • Turnbull F.
        • Blood Pressure Lowering Treatment Trialists' Collaboration
        Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
        Lancet. 2003; 362: 1527-1535
        • UK Prospective Diabetes Study Group
        Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
        BMJ. 1998; 317: 703-713
        • Law M.R.
        • Morris J.K.
        • Wald N.J.
        Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
        BMJ. 2009; 338: b1665
        • Wang J.G.
        • Staessen J.A.
        • Franklin S.S.
        • et al.
        Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome.
        Hypertension. 2005; 45: 907-913
        • Sica D.A.
        Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.
        Drugs. 2002; 62: 443-462
        • Weber M.A.
        Creating a combination antihypertensive regimen: what does the research show?.
        J Clin Hypertens. 2003; 5: 12-20
        • Morgan T.
        • Anderson A.
        A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension.
        Am J Hypertens. 2002; 15: 544-549
        • Allemann Y.
        • Fraile B.
        • Lambert M.
        • et al.
        Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
        J Clin Hypertens. 2008; 10: 185-194
        • Chrysant S.G.
        • Melino M.
        • Karki S.
        • et al.
        The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
        Clin Ther. 2008; 30: 587-604
        • NICE
        Hypertension: The clinical management of primary hypertension in adults.
        National Clinical Guideline Centre, August 2011
        • Fogari R.
        • Zoppi A.
        • Derosa G.
        • et al.
        Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
        J Hum Hypertens. 2007; 21: 220-224
        • Croom K.F.
        • Curran M.P.
        • Goa K.L.
        • Perry C.M.
        Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
        Drugs. 2004; 64: 999-1028
        • Haria M.
        • Wagstaff A.J.
        Drugs. 1995; 50: 560-586
        • Epstein B.J.
        • Vogel K.
        • Palmer B.F.
        Dihydropyridine calcium channel antagonists in the management of hypertension.
        Drugs. 2007; 67: 1309-1327
        • Bobrie G.
        • I-COMBINE Study Investigators
        I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, Phase III, prospective, randomized, open-babel with blinded-end point evaluation study.
        Clin Ther. 2012; 34: 1698-1712
        • O'Brien E.
        • Pickering T.
        • Asmar R.
        • et al.
        Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults.
        Blood Press Monit. 2002; 7: 3-17
        • Smith T.R.
        • Philipp T.
        • Vaisse B.
        Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.
        J Clin Hypertens. 2007; 9: 355-364
        • Philipp T.
        • Smith T.R.
        • Glazer R.
        Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
        Clin Ther. 2007; 29: 563-580
        • Flack J.M.
        • Calhoun D.A.
        • Satlin L.
        • et al.
        Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study.
        J Hum Hypertens. 2009; 23: 479-489
        • Fogari R.
        • Zoppi A.
        • Mugellini A.
        • et al.
        Efficacy and safety of two treatment combinations of hypertension in very elderly patients.
        Arch Gerontol Geriatr. 2009; 48: 401-405
        • Calhoun D.A.
        • Lacourcière Y.
        • Chiang Y.T.
        • Glazer R.D.
        Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
        Hypertension. 2009; 54: 32-39
        • Oparil S.
        • Giles T.
        • Ofili E.O.
        • et al.
        Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.
        J Hypertens. 2011; 29: 161-170
        • Wald D.S.
        • Law M.
        • Morris J.K.
        • et al.
        Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
        Am J Med. 2009; 122: 290-300
        • Pimenta E.
        • Oparil S.
        Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination.
        Vasc Health Risk Manag. 2008; 4: 653-664